PI
MGNX icon

Pennant Investors’s MacroGenics MGNX Stock Holding History

Pennant Investors’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-43,800
Closed -$186K – 34
2024
Q2 		$186K Hold
43,800
– – 0.05% 40
2024
Q1 		$645K Hold
43,800
– – 0.16% 18
2023
Q4 		$421K Buy
+43,800
New +$303K 0.09% 25

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pennant Investors's MGNX Position: Q3 2024 in Review

Pennant Investors sold out of MacroGenics (MGNX) in Q3 2024, closing a stake of 43,800 shares — an estimated $186K sold.

Pennant Investors first reported a position in MGNX in Q4 2023 and held it in 3 quarters. The position peaked at $645K in Q1 2024. 124 funds tracked by Wall St. Rank hold MGNX as of Q3 2024.

  • Pennant Investors reported no remaining MacroGenics position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 43,800 MacroGenics shares in Q3 2024, an estimated $186K.
  • Pennant Investors first reported a position in MacroGenics in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's MacroGenics position peaked at $645K in Q1 2024.
  • 124 funds tracked by Wall St. Rank held MacroGenics as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.